Home > Insider Trading > Filing (0001209191-20-004740)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1322505	Albireo Pharma Inc.	ALBO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1741553	Jason Duncan	C/O Albireo Pharma Inc. 10 Post Office Square, Suite 1000 Boston MA 02109	Chief Legal Officer And Gc	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-01-22	447	$23.97	4,553	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2020-01-21	31,500	$0.00	31,500	$24.67

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
31,500		2030-01-20	No	4	A	Direct

Footnotes

Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.95 to $24.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Represents 803 shares of common stock and 3,750 restricted stock units.
This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021.